Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-008656
Filing Date
2023-05-09
Accepted
2023-05-09 07:16:04
Documents
62
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vygr-20230331x10q.htm   iXBRL 10-Q 1305529
2 EX-10.5 vygr-20230331xex10d5.htm EX-10.5 59623
3 EX-31.1 vygr-20230331xex31d1.htm EX-31.1 12995
4 EX-31.2 vygr-20230331xex31d2.htm EX-31.2 13776
5 EX-32.1 vygr-20230331xex32d1.htm EX-32.1 10726
6 GRAPHIC vygr-20230331x10q006.jpg GRAPHIC 92400
  Complete submission text file 0001558370-23-008656.txt   6054239

Data Files

Seq Description Document Type Size
7 EX-101.SCH vygr-20230331.xsd EX-101.SCH 47734
8 EX-101.CAL vygr-20230331_cal.xml EX-101.CAL 46157
9 EX-101.DEF vygr-20230331_def.xml EX-101.DEF 186756
10 EX-101.LAB vygr-20230331_lab.xml EX-101.LAB 391654
11 EX-101.PRE vygr-20230331_pre.xml EX-101.PRE 301091
56 EXTRACTED XBRL INSTANCE DOCUMENT vygr-20230331x10q_htm.xml XML 936062
Mailing Address 64 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 64 SIDNEY STREET CAMBRIDGE MA 02139 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37625 | Film No.: 23899952
SIC: 2836 Biological Products, (No Diagnostic Substances)